Tags

Type your tag names separated by a space and hit enter

The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence.
Eur J Pediatr 2014; 173(10):1327-37EJ

Abstract

We aimed to systematically evaluate evidence on the effectiveness of Lactobacillus reuteri DSM 17938 (L. reuteri) for treating and preventing diseases in infants and children. MEDLINE and the Cochrane Library were searched in December 2013, with no language restrictions, for relevant randomized controlled trials (RCTs) and meta-analyses. The search was updated in April 2014. One systematic review and 14 RCTs met the inclusion criteria. The use of L. reuteri may be considered in the management of acute gastroenteritis as an adjunct to rehydration. There is some evidence that L. reuteri is effective in reducing the incidence of diarrhea in children attending day care centers. There is no evidence of effectiveness of L. reuteri in preventing nosocomial diarrhea in children. The administration of L. reuteri is likely to reduce crying time in infants with infantile colic in exclusively or predominantly exclusively breast-fed infants, but not in formula-fed infants. More studies are needed. Preliminary data suggest that L. reuteri may be effective in the prevention of some functional gastrointestinal disorders, such as colic and regurgitation. This innovative approach needs further evaluation by an independent research team. Preliminary evidence provides a rationale for further assessing the efficacy of L. reuteri for treating functional constipation or functional abdominal pain. However, it is too soon to recommend the routine use of L. reuteri for these conditions. There are no safety concerns with regard to the use of L. reuteri in nonimmunocompromised subjects. There are also data to support the safety of using L. reuteri in preterm infants.

CONCLUSION

Our results precisely define current evidence on the effects of the administration of L. reuteri DSM 17938 to the pediatric population.

Authors+Show Affiliations

Department of Paediatrics, The Medical University of Warsaw, 01184, Warsaw, Działdowska 1, Poland, magdalena.urb@gmail.com.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review

Language

eng

PubMed ID

24819885

Citation

Urbańska, Magdalena, and Hania Szajewska. "The Efficacy of Lactobacillus Reuteri DSM 17938 in Infants and Children: a Review of the Current Evidence." European Journal of Pediatrics, vol. 173, no. 10, 2014, pp. 1327-37.
Urbańska M, Szajewska H. The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. Eur J Pediatr. 2014;173(10):1327-37.
Urbańska, M., & Szajewska, H. (2014). The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. European Journal of Pediatrics, 173(10), pp. 1327-37. doi:10.1007/s00431-014-2328-0.
Urbańska M, Szajewska H. The Efficacy of Lactobacillus Reuteri DSM 17938 in Infants and Children: a Review of the Current Evidence. Eur J Pediatr. 2014;173(10):1327-37. PubMed PMID: 24819885.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. AU - Urbańska,Magdalena, AU - Szajewska,Hania, Y1 - 2014/05/13/ PY - 2014/03/17/received PY - 2014/04/23/accepted PY - 2014/04/22/revised PY - 2014/5/14/entrez PY - 2014/5/14/pubmed PY - 2015/5/30/medline SP - 1327 EP - 37 JF - European journal of pediatrics JO - Eur. J. Pediatr. VL - 173 IS - 10 N2 - UNLABELLED: We aimed to systematically evaluate evidence on the effectiveness of Lactobacillus reuteri DSM 17938 (L. reuteri) for treating and preventing diseases in infants and children. MEDLINE and the Cochrane Library were searched in December 2013, with no language restrictions, for relevant randomized controlled trials (RCTs) and meta-analyses. The search was updated in April 2014. One systematic review and 14 RCTs met the inclusion criteria. The use of L. reuteri may be considered in the management of acute gastroenteritis as an adjunct to rehydration. There is some evidence that L. reuteri is effective in reducing the incidence of diarrhea in children attending day care centers. There is no evidence of effectiveness of L. reuteri in preventing nosocomial diarrhea in children. The administration of L. reuteri is likely to reduce crying time in infants with infantile colic in exclusively or predominantly exclusively breast-fed infants, but not in formula-fed infants. More studies are needed. Preliminary data suggest that L. reuteri may be effective in the prevention of some functional gastrointestinal disorders, such as colic and regurgitation. This innovative approach needs further evaluation by an independent research team. Preliminary evidence provides a rationale for further assessing the efficacy of L. reuteri for treating functional constipation or functional abdominal pain. However, it is too soon to recommend the routine use of L. reuteri for these conditions. There are no safety concerns with regard to the use of L. reuteri in nonimmunocompromised subjects. There are also data to support the safety of using L. reuteri in preterm infants. CONCLUSION: Our results precisely define current evidence on the effects of the administration of L. reuteri DSM 17938 to the pediatric population. SN - 1432-1076 UR - https://www.unboundmedicine.com/medline/citation/24819885/full_citation L2 - https://dx.doi.org/10.1007/s00431-014-2328-0 DB - PRIME DP - Unbound Medicine ER -